RU2010141996A - Ингибитор ммр-2 и/или ммр-9 - Google Patents
Ингибитор ммр-2 и/или ммр-9 Download PDFInfo
- Publication number
- RU2010141996A RU2010141996A RU2010141996/04A RU2010141996A RU2010141996A RU 2010141996 A RU2010141996 A RU 2010141996A RU 2010141996/04 A RU2010141996/04 A RU 2010141996/04A RU 2010141996 A RU2010141996 A RU 2010141996A RU 2010141996 A RU2010141996 A RU 2010141996A
- Authority
- RU
- Russia
- Prior art keywords
- mmp
- inhibitor
- group
- substituents
- treatment
- Prior art date
Links
- 102100026802 72 kDa type IV collagenase Human genes 0.000 title claims abstract 9
- 101710151806 72 kDa type IV collagenase Proteins 0.000 title claims abstract 9
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 title claims abstract 9
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 title claims abstract 9
- 239000003112 inhibitor Substances 0.000 title claims abstract 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 125000001424 substituent group Chemical group 0.000 claims abstract 4
- 150000007979 thiazole derivatives Chemical class 0.000 claims abstract 4
- XDBHURGONHZNJF-UHFFFAOYSA-N 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid Chemical group C1=C(OCC)C(OCC)=CC=C1C1=NC(C=2N=C(C=CC=2)C(O)=O)=CS1 XDBHURGONHZNJF-UHFFFAOYSA-N 0.000 claims abstract 2
- 206010014561 Emphysema Diseases 0.000 claims abstract 2
- 206010016654 Fibrosis Diseases 0.000 claims abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 230000004761 fibrosis Effects 0.000 claims abstract 2
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
Abstract
1. Ингибитор ММР-2 и/или ММР-9, включающий в качестве активного ингредиента, по меньшей мере, одно соединение, выбранное из группы, состоящей из производных тиазола, представленных формулой 1): ! ! где R1 представляет собой фенильную группу, которая может иметь от 1 до 3 низших алкоксигрупп в качестве заместителей у фенильного кольца, и R2 представляет собой пиридильную группу, которая может иметь от 1 до 3 карбоксильных групп в качестве заместителей у пиридинового кольца, и их солей. ! 2. Ингибитор ММР-2 и/или ММР-9 по п.1, где производное тиазола представляет собой 6-[2-(3,4-диэтоксифенил)тиазол-4-ил]пиридин-2-карбоновую кислоту или ее соль. ! 3. Ингибитор ММР-2 и/или ММР-9 по п.1 или 2 для применения при лечении фиброза. ! 4. Ингибитор ММР-2 и/или ММР-9 по п.1 или 2 для применения при лечении легочной эмфиземы.
Claims (4)
1. Ингибитор ММР-2 и/или ММР-9, включающий в качестве активного ингредиента, по меньшей мере, одно соединение, выбранное из группы, состоящей из производных тиазола, представленных формулой 1):
где R1 представляет собой фенильную группу, которая может иметь от 1 до 3 низших алкоксигрупп в качестве заместителей у фенильного кольца, и R2 представляет собой пиридильную группу, которая может иметь от 1 до 3 карбоксильных групп в качестве заместителей у пиридинового кольца, и их солей.
2. Ингибитор ММР-2 и/или ММР-9 по п.1, где производное тиазола представляет собой 6-[2-(3,4-диэтоксифенил)тиазол-4-ил]пиридин-2-карбоновую кислоту или ее соль.
3. Ингибитор ММР-2 и/или ММР-9 по п.1 или 2 для применения при лечении фиброза.
4. Ингибитор ММР-2 и/или ММР-9 по п.1 или 2 для применения при лечении легочной эмфиземы.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008-065455 | 2008-03-14 | ||
| JP2008065455 | 2008-03-14 | ||
| PCT/JP2009/055545 WO2009113736A1 (en) | 2008-03-14 | 2009-03-13 | Mmp-2 and/or mmp-9 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010141996A true RU2010141996A (ru) | 2012-04-20 |
| RU2487131C2 RU2487131C2 (ru) | 2013-07-10 |
Family
ID=40613081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010141996/04A RU2487131C2 (ru) | 2008-03-14 | 2009-03-13 | Ингибитор ммр-2 и/или ммр-9 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20110054179A1 (ru) |
| EP (1) | EP2280708A1 (ru) |
| JP (2) | JP2011513203A (ru) |
| KR (1) | KR20100135255A (ru) |
| CN (3) | CN101969949B (ru) |
| AR (1) | AR070882A1 (ru) |
| AU (1) | AU2009224209B2 (ru) |
| BR (1) | BRPI0909288A2 (ru) |
| CA (1) | CA2718005A1 (ru) |
| IL (2) | IL207816A0 (ru) |
| MX (1) | MX2010010073A (ru) |
| NZ (1) | NZ587591A (ru) |
| RU (1) | RU2487131C2 (ru) |
| SG (1) | SG188852A1 (ru) |
| TW (1) | TWI436767B (ru) |
| UA (1) | UA108979C2 (ru) |
| WO (1) | WO2009113736A1 (ru) |
| ZA (1) | ZA201005991B (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2617726A4 (en) * | 2010-09-17 | 2014-05-14 | Takeda Pharmaceutical | DIABETES THERAPEUTIC |
| EP3837256B1 (en) | 2018-08-17 | 2023-03-08 | Novartis AG | Urea compounds and compositions as smarca2/brm-atpase inhibitors |
| AU2023244347A1 (en) * | 2022-03-29 | 2024-10-03 | The Trustees Of The University Of Pennsylvania | Methods of treating, ameliorating and/or preventing fibrodysplasia ossificans progressiva and heterotopic ossification, and kits for the same |
| WO2023204170A1 (ja) * | 2022-04-18 | 2023-10-26 | 大正製薬株式会社 | Ｍｍｐ２阻害作用を有する化合物を有効成分として含有する肺の炎症及び線維症の予防又は治療薬 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA962269A (en) * | 1971-05-05 | 1975-02-04 | Uniroyal Ltd. | Thiazoles, and their use as insecticides |
| US5639770A (en) * | 1992-05-29 | 1997-06-17 | Otsuka Pharmaceutical Co., Ltd. | Thiazole derivatives |
| JP3622015B2 (ja) * | 1992-10-08 | 2005-02-23 | 敏一 中村 | 肺傷害治療剤 |
| MY128323A (en) * | 1996-09-30 | 2007-01-31 | Otsuka Pharma Co Ltd | Thiazole derivatives for inhibition of cytokine production and of cell adhesion |
| AU2001238288A1 (en) * | 2000-02-16 | 2001-08-27 | University Of Nebraska Medical Center | Method and compositions for treating fibrotic diseases |
| GB0007405D0 (en) * | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| EP1199074A1 (en) * | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| WO2002046186A1 (en) * | 2000-12-08 | 2002-06-13 | Takeda Chemical Industries, Ltd. | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof |
| JP3713577B2 (ja) * | 2001-07-24 | 2005-11-09 | 大塚製薬株式会社 | 慢性閉塞性肺疾患治療薬 |
| DK1411936T3 (da) * | 2001-07-24 | 2005-12-27 | Otsuka Pharma Co Ltd | Anvendelse af thiazolderivater i fremstillingen af et medikament til behandling af kronisk obstruktiv lungesygdom |
| KR20040081182A (ko) * | 2002-02-05 | 2004-09-20 | 다이닛본 세이야꾸 가부시끼가이샤 | 엘라스타제-저해 활성을 가진 이종고리 화합물 및 그 중간체 |
| GB0217504D0 (en) * | 2002-07-29 | 2002-09-04 | Novartis Ag | Organic compounds |
| BR0313755A (pt) * | 2002-08-23 | 2005-06-21 | Rigel Pharmaceuticals Inc | Composto, métodos para inibir a replicação ou proliferação de um vìrion da hepatite c e para tratar ou prevenir uma infecção por hcv, e, composição |
| UA80295C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| WO2006008119A1 (en) * | 2004-07-16 | 2006-01-26 | Proteosys Ag | Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases |
| JP5846711B2 (ja) * | 2005-06-09 | 2016-01-20 | メダ アーベー | 炎症性疾患の治療のための方法及び組成物 |
| US20070254913A1 (en) * | 2006-04-19 | 2007-11-01 | Dunn Robert F | Phosphodiesterase 4 inhibitors |
| TWI436761B (zh) * | 2006-06-19 | 2014-05-11 | Otsuka Pharma Co Ltd | 使用噻唑衍生物之方法 |
| ES2378281T3 (es) * | 2006-07-05 | 2012-04-10 | Nycomed Gmbh | Combinación de atorvastatina con un inhibidor de fosfodiesterasa 4 para el tratamiento de neumopatías inflamatorias |
-
2009
- 2009-03-13 JP JP2010536255A patent/JP2011513203A/ja active Pending
- 2009-03-13 SG SG2013016746A patent/SG188852A1/en unknown
- 2009-03-13 CA CA2718005A patent/CA2718005A1/en not_active Abandoned
- 2009-03-13 BR BRPI0909288-9A patent/BRPI0909288A2/pt not_active IP Right Cessation
- 2009-03-13 CN CN2009801087584A patent/CN101969949B/zh not_active Expired - Fee Related
- 2009-03-13 TW TW098108215A patent/TWI436767B/zh not_active IP Right Cessation
- 2009-03-13 EP EP09719488A patent/EP2280708A1/en not_active Withdrawn
- 2009-03-13 NZ NZ587591A patent/NZ587591A/xx not_active IP Right Cessation
- 2009-03-13 MX MX2010010073A patent/MX2010010073A/es active IP Right Grant
- 2009-03-13 RU RU2010141996/04A patent/RU2487131C2/ru not_active IP Right Cessation
- 2009-03-13 AU AU2009224209A patent/AU2009224209B2/en not_active Ceased
- 2009-03-13 KR KR1020107022827A patent/KR20100135255A/ko not_active Ceased
- 2009-03-13 UA UAA201012145A patent/UA108979C2/ru unknown
- 2009-03-13 AR ARP090100897A patent/AR070882A1/es unknown
- 2009-03-13 CN CN201310533925.8A patent/CN103622962A/zh active Pending
- 2009-03-13 CN CN2013103353496A patent/CN103463084A/zh active Pending
- 2009-03-13 US US12/922,374 patent/US20110054179A1/en not_active Abandoned
- 2009-03-13 WO PCT/JP2009/055545 patent/WO2009113736A1/en not_active Ceased
-
2010
- 2010-08-23 ZA ZA2010/05991A patent/ZA201005991B/en unknown
- 2010-08-26 IL IL207816A patent/IL207816A0/en unknown
-
2013
- 2013-09-17 IL IL228484A patent/IL228484A0/en unknown
-
2014
- 2014-09-01 JP JP2014176705A patent/JP2014221839A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0909288A2 (pt) | 2015-08-18 |
| RU2487131C2 (ru) | 2013-07-10 |
| ZA201005991B (en) | 2011-10-26 |
| KR20100135255A (ko) | 2010-12-24 |
| CN103622962A (zh) | 2014-03-12 |
| TWI436767B (zh) | 2014-05-11 |
| TW200942237A (en) | 2009-10-16 |
| NZ587591A (en) | 2012-10-26 |
| AR070882A1 (es) | 2010-05-12 |
| IL228484A0 (en) | 2013-12-31 |
| CN101969949A (zh) | 2011-02-09 |
| CA2718005A1 (en) | 2009-09-17 |
| US20110054179A1 (en) | 2011-03-03 |
| WO2009113736A1 (en) | 2009-09-17 |
| JP2014221839A (ja) | 2014-11-27 |
| EP2280708A1 (en) | 2011-02-09 |
| CN103463084A (zh) | 2013-12-25 |
| AU2009224209B2 (en) | 2015-01-22 |
| MX2010010073A (es) | 2010-10-04 |
| UA108979C2 (ru) | 2015-07-10 |
| CN101969949B (zh) | 2013-12-25 |
| IL207816A0 (en) | 2010-12-30 |
| SG188852A1 (en) | 2013-04-30 |
| JP2011513203A (ja) | 2011-04-28 |
| AU2009224209A1 (en) | 2009-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009136178A (ru) | Нематоцидная композиция и способ ее применения | |
| CL2022001844A1 (es) | Compuesto de iminoarilo sustituido con derivado de ácido carboxílico, método de preparación, composición y uso | |
| MEP10009A (en) | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-hpyrrole derivatives as acid secretion inhibitors | |
| AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
| RU2006101890A (ru) | Производные тиазолилпиперидина в качестве ингибиторов мпб | |
| NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
| RU2011137457A (ru) | Пестицыдные композиции | |
| RU2007139453A (ru) | Гетеробициклические ингибиторы вируса гепатита с (hcv) | |
| UA99930C2 (ru) | Фунгицидная композиция и способы борьбы с вредными грибами | |
| ATE442356T1 (de) | 1-essigsäureindolderivate mit pgd2- antagonistischer wirkung | |
| EP1371650A4 (en) | ACTIVATED RECEPTOR ACTIVATOR BY PEROXYSOME PROLIFIERS | |
| EA201170176A1 (ru) | Ингибитор stat3, содержащий хинолинкарбоксамидное производное в качестве активного ингредиента | |
| NO20051051L (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutiske midler | |
| MX2009000675A (es) | Concentrados acuosos de principios activos con efecto herbicida. | |
| NO20080325L (no) | Forbindelser og deres salter som er spesifikke overfor PPAR-reseptorer og EGF-reseptorer samt deres anvendelse innen medisin | |
| DE60306539D1 (de) | Nicht-nukleosidische inhibitoren der reverse transkriptase | |
| EA200600878A1 (ru) | Производные феноксиуксусных кислот, применимые в качестве двойных агонистов активируемого пероксисомным пролифератором рецептора ( ppar ) | |
| ATE388147T1 (de) | Thiazolderivate als a2b-antagonisten | |
| RU2010146954A (ru) | 2-(замещенный фенил)-6-гидрокси или алкокси-5-замещенные-4-пиримидинкарбоксилаты и их применение в качестве гербицидов | |
| RU2017117179A (ru) | Производные пиридооксазинона в качестве ингибиторов tnap | |
| RU2006139140A (ru) | Средства и способы для лечения нарушений свертываемости | |
| RU2012122066A (ru) | Защита злаковых культур гербицидного повреждения 6-амино-2-(замещенный фенил)-5-замещенный-4-пиримидинкарбоксилатом | |
| DE60316780D1 (de) | Modulatoren von peroxisome proliferator-aktivierten rezeptoren | |
| NZ587591A (en) | Diarylthiazole derivatives such as tetomilast as mmp-2 and/or mmp-9 inhibitors | |
| RU2010114928A (ru) | Биологически активные вещества, подавляющие патогенные бактерии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160314 |